Seres Therapeutics, Inc. (MCRB)

Market Cap	156.31M
Revenue (ttm)	126.33M
Net Income (ttm)	-25.48M
Shares Out	170.74M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,746,107
Open	0.932
Previous Close	0.921
Day's Range	0.915 - 0.962
52-Week Range	0.540 - 2.050
Beta	2.08
Analysts	Buy
Price Target	5.63 (+514.97%)
Earnings Date	Nov 13, 2024

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2015
• Employees: 233
• Stock Exchange: NASDAQ
• Ticker Symbol: MCRB
• Website: https://www.serestherapeutics.com

Financial Performance

In 2023, Seres Therapeutics's revenue was $126.33 million, an increase of 1672.24% compared to the previous year's $7.13 million. Losses were -$113.72 million, -54.54% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is $5.63, which is an increase of 514.97% from the latest price.

Price Target

$5.63

(514.97% upside)

Analyst Consensus: Buy